Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans (#6113)

University of California San Francisco (UCSF)

Status and phase

Completed

Phase 1

Conditions

Healthy

Type 2 Diabetes Mellitus

Treatments

Drug: Metformin

Study type

Interventional

Funder types

Other

Identifiers

NCT01681693

6113

Details and patient eligibility

About

The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. The investigators will study individuals with particular genotypes of the human organic cation transporter, (hOCT3), and the multidrug and toxin extrusion transporter, MATE1 to test the hypothesis that genetic variation in hOCT3 and hMATE1 are associated with variation in the pharmacokinetics and/or pharmacodynamics of the antidiabetic agent, metformin.

Full description

To investigate the potential association of polymorphic genetic variants MATE1 and OCT3 with altered response to metformin, a genotype to phenotype strategy is employed. Specifically, the investigators will evaluate this hypothesis in African-Americans, a population which has a high incidence of type 2 diabetes and which has high variant allele frequencies (44.5% for MATE1-66T>C and 11.3% in OCT3-81G>delGA) relative to other ethic groups. To assess the effects of these variants on metformin response, the investigators will measure metformin renal clearance (pharmacokinetics of metformin), and plasma glucose and insulin levels (pharmacodynamic response) in healthy and diabetic patients who carry either the reference or variant alleles.

Enrollment

33 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Subjects self-identify racial background, identify themselves, parents and four grandparents as African American
Subject status is healthy volunteer from t In the event that diabetes is indicated in a normal subject based on OGTT results, we will notify the patients' primary care physician. he SOPHIE cohort OR diagnosis of T2DM based on American Diabetes Association (ADA) criteria
Subjects over 18 years old and below 60 years
Subjects who are healthy on the basis of medical history, physical examinations and laboratory tests if healthy volunteer from SOPHIE
Subjects who agree with the written informed consent to participate in the study

Exclusion criteria

Unable to confirm African-American ethnicity
Under 18 years old
Pregnant or lactating women (female subjects will have a urine pregnancy test at the screening visit).
Prior history of any allergic reaction to metformin
Has a risk of congestive heart failure requiring pharmacologic treatment (medical history)
Has a prior history of renal* or hepatic dysfunction (renal and hepatic function will be evaluated based on screening blood tests conducted prior to study enrollment)
Risk of urinary or gastric retention or narrow-angle glaucoma (by medical history examination)
Impaired renal function (e.g as suggested by abnormal creatinine clearance, eGFR <60 or serum creatinine >1.4 mg/dl in females and >1.5 mg/dl in males) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction (heart attack), and septicemia, abnormal heart rhythms (tachyarrhythmias; heart beat > 100 beats per minute).
Impaired hepatic function (> 1.5 times the upper limit of normal)
Evidence of anemia (hemoglobin <10 g)
Taking a medication that could confound study results, such as known substrates or inhibitors of OCT3 and MATE1, such as cimetidine.
They do not provide consent to participate in the study.